Skip to main content

Advertisement

SpringerLink
Log in

Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The impact of supportive medications on patient-reported outcomes (PROs) has not been systematically evaluated. We describe the supportive medications used by treatment-naïve lung cancer patients and assess their association with PROs from MD Anderson Symptom Inventory (MDASI).

Methods

Treatment-naïve lung cancer patients who completed PROs from MDASI at the initial visit to MD Anderson Cancer Center were included. Medications from the initial visit were abstracted from the electronic medical records system and categorized into therapeutic classes based on U.S. Pharmacopeia v7.0. A chi-square or Mann-Whitney U test was conducted as appropriate.

Results

Among 459 patients, ~ 50% took any analgesics and 25% were on opioids. One-third of patients with moderate-severe pain were not on any analgesics. Patients taking opioids had significantly worse median pain scores (6 vs. 0) compared with those not taking any analgesics (p < 0.0001). Higher proportion of patients with moderate-severe pain took opioids compared with those with mild pain (52% vs. 16%, p < 0.0001). Patients on opioids also reported significantly worse scores for five other cancer-specific core symptoms and all six symptoms rating interference with daily life. Only 15% of patients with higher composite score for depression-related symptoms were on antidepressants. However, patients taking antidepressants did not significantly differ in any individual MDASI symptom scores compared with those not on antidepressants (p = 0.4858).

Conclusions

Our results suggest a need for better screening for pain and depression and optimization of pain management in treatment-naïve lung cancer patients since their poor functional status may result in suboptimal cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Basch E (2016) Missing patients’ symptoms in cancer care delivery--the importance of patient-reported outcomes. JAMA Oncol 2:433–434

    Article  Google Scholar 

  2. Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, Chen WH, Sridhara R, Farrell AT, Keegan P, Kim G, Pazdur R (2016) Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res 22:1553–1558

    Article  CAS  Google Scholar 

  3. Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24:3669–3676

    Article  Google Scholar 

  4. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909

    Article  Google Scholar 

  5. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632

    Article  Google Scholar 

  6. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St. Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:dju244

    Article  Google Scholar 

  7. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490

    Article  Google Scholar 

  8. Iyer S, Roughley A, Rider A, Taylor-Stokes G (2014) The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer 22:181–187

    Article  Google Scholar 

  9. Lou VW, Chen EJ, Jian H et al (2017) Respiratory symptoms, sleep, and quality of life in patients with advanced lung cancer. J Pain Symptom Manag 53:250–256 e251

    Article  Google Scholar 

  10. Lemonnier I, Baumann C, Jolly D, Arveux P, Woronoff-Lemsi MC, Velten M, Guillemin F (2011) Solitary pulmonary nodules: consequences for patient quality of life. Qual Life Res 20:101–109

    Article  Google Scholar 

  11. Lheureux M, Raherison C, Vernejoux JM, Nguyen L, Nocent C, Tunon de Lara M, Taytard A (2004) Quality of life in lung cancer: does disclosure of the diagnosis have an impact? Lung Cancer 43:175–182

    Article  CAS  Google Scholar 

  12. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240

    Article  CAS  Google Scholar 

  13. Blanco R, Maestu I, de la Torre MG, Cassinello A, Nuñez I (2015) A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol 26:451–463

    Article  CAS  Google Scholar 

  14. Repetto L, Balducci L (2002) A case for geriatric oncology. Lancet Oncol 3:289–297

    Article  Google Scholar 

  15. Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, Khakoo AY, Kirch RA, Kwitkowski VE, Liao Z, Skillings J (2012) Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol 9:471–478

    Article  CAS  Google Scholar 

  16. Yates JW (2001) Comorbidity considerations in geriatric oncology research. CA Cancer J Clin 51:329–336

    Article  CAS  Google Scholar 

  17. Basch E (2013) Toward patient-centered drug development in oncology. N Engl J Med 369:397–400

    Article  CAS  Google Scholar 

  18. Tirodkar MA, Acciavatti N, Roth LM, Stovall E, Nasso SF, Sprandio J, Tofani S, Lowry M, Friedberg MW, Smith-McLallen A, Chanin J, Scholle SH (2015) Lessons from early implementation of a patient-centered care model in oncology. J Oncol Pract 11:456–461

    Article  Google Scholar 

  19. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89:1634–1646

    Article  CAS  Google Scholar 

  20. Giuliani ME, Milne RA, Puts M et al (2016) The prevalence and nature of supportive care needs in lung cancer patients. Curr Oncol 23:258–265

    Article  CAS  Google Scholar 

  21. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260

    Article  Google Scholar 

  22. Cleeland CS, Zhao F, Chang VT, Sloan JA, O’Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ (2013) The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the eastern cooperative oncology group symptom outcomes and practice patterns study. Cancer 119:4333–4340

    Article  Google Scholar 

  23. Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CS (2011) Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist 16:217–227

    Article  Google Scholar 

  24. Jones D, Vichaya EG, Cleeland CS, Cohen L, Thekdi SM, Wang XS, Fisch MJ (2014) Screening for depressed mood in patients with cancer using the MD Anderson Symptom Inventory: investigation of a practical approach for the oncologist. J Oncol Pract 10:e95–e102

    Article  Google Scholar 

  25. National Comprehensive Cancer Network. Adult cancer pain (version 1.2018). https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed April 11

  26. Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC (1996) Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 67:267–273

    Article  CAS  Google Scholar 

  27. Geisser ME, Cano A, Foran H (2006) Psychometric properties of the mood and anxiety symptom questionnaire in patients with chronic pain. Clin J Pain 22:1–9

    Article  Google Scholar 

  28. Shacham S, Dar R, Cleeland CS (1984) The relationship of mood state to the severity of clinical pain. Pain 18:187–197

    Article  CAS  Google Scholar 

  29. Collier R (2018) “Complainers, malingerers and drug-seekers” - the stigma of living with chronic pain. CMAJ 190:E204–E205

    Article  Google Scholar 

  30. Jamison RN, Sheehan KA, Scanlan E et al (2014) Beliefs and attitudes about opioid prescribing and chronic pain management: survey of primary care providers. J Opioid Manag 10:375–382

    Article  Google Scholar 

  31. Kanouse AB, Compton P (2015) The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. J Pain Palliat Care Pharmacother 29:102–114

    Article  Google Scholar 

  32. Spitz A, Moore AA, Papaleontiou M, Granieri E, Turner BJ, Reid MC (2011) Primary care providers’ perspective on prescribing opioids to older adults with chronic non-cancer pain: a qualitative study. BMC Geriatr 11:35

    Article  Google Scholar 

  33. Waugh OC, Byrne DG, Nicholas MK (2014) Internalized stigma in people living with chronic pain. J Pain 15:550 e551–550 e510

    Article  Google Scholar 

  34. Centers for Disease C, Prevention (2011) Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep 60:1487–1492

    Google Scholar 

  35. Reuben DB, Alvanzo AA, Ashikaga T et al (2015) National Institutes of Health pathways to prevention workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med 162:295–300

    Article  Google Scholar 

  36. Paulozzi LJ, Mack KA, Hockenberry JM et al (2014) Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines - United States. 2012 MMWR Morb Mortal Wkly Rep 63:563–568

    PubMed  Google Scholar 

  37. Besson JM The complexity of physiopharmacologic aspects of pain(1997) La complexité des aspects physiopharmacologiques de la douleur. Drugs 53(Suppl 2):1–9

    Article  CAS  Google Scholar 

  38. Peppin JF, Cheatle MD, Kirsh KL, McCarberg BH (2015) The complexity model: a novel approach to improve chronic pain care. Pain Med 16:653–666

    Article  Google Scholar 

  39. Janberidze E, Hjermstad MJ, Brunelli C, Loge JH, Lie HC, Kaasa S, Knudsen AK, on behalf of EURO IMPACT (2014) The use of antidepressants in patients with advanced cancer--results from an international multicentre study. Psychooncology 23:1096–1102

    Article  Google Scholar 

  40. Mitchell AJ, Yadegarfar M, Gill J, Stubbs B (2016) Case finding and screening clinical utility of the Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. BJPsych Open 2:127–138

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Health Building-2, 4849 Calhoun Rd., Houston, TX, 77204, USA

    Johnny M. Hoang, Dozie N. Dike, Jaekyu Lee & Meghana V. Trivedi

  2. Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Health Building-2, 4849 Calhoun Rd., Houston, TX, 77204, USA

    Navneet Upadhyay, Michael L. Johnson & Hua Chen

  3. Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA

    Charles S. Cleeland & Tito Mendoza

Authors
  1. Johnny M. Hoang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Navneet Upadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dozie N. Dike
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jaekyu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael L. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charles S. Cleeland
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tito Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Meghana V. Trivedi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meghana V. Trivedi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 32 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoang, J.M., Upadhyay, N., Dike, D.N. et al. Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients. Support Care Cancer 28, 1809–1816 (2020). https://doi.org/10.1007/s00520-019-05004-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-019-05004-8

Keywords

Search

Navigation